Utility and direct costs: Ankylosing spondylitis compared with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 66, Issue 6, 2007, Pages 727-731

  Verstappen, S M M ^a   Jacobs, J W G ^a   Van Der Heijde, D M ^b   Van Der Linden, Sj ^b   Verhoef, C M ^c   Bijlsma, J W J ^a   Boonen, A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Flevo Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DISEASE DURATION; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; MALE; NETHERLANDS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; NEEDS ASSESSMENT; NETHERLANDS; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; SPONDYLITIS, ANKYLOSING;

EID: 34249788696     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.061283     Document Type: Article

References (22)

1. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
2. Boonen A, van der Heijde D. Review of the costs of illness of ankylosing spondylitis and methodologic notes. Expert Rev Pharmacoecon Outcomes Res 2005;5:163-81.
3. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28-33.
4. Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 2005;23:243-57.
5. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
6. Busschbach JJ, McDonnell J, Essink-Bot ML, van Hout BA. Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D. J Health Econ 1999;18:551-71.
7. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Ruttenvan Mölken M, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
8. Boonen A, van der Heijde D, Landewe R, Guillemin F, Rutten-van Mölken M, Dougados M, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003;62:732-40.
9. Verstappen SM, Verkleij H, Bijlsma JW, Buskens E, Kruize AA, Heurkens AHM, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004;63:817-24.
10. Verstappen SM, Boonen A, Bijlsma JW, Buskens E, Verkleij H, Schenk Y, et al. Working status among Dutch patients with rheumatoid arthritis: work disability and working conditions. Rheumatology (Oxford) 2005;44:202-6.
11. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Guideline for cost-of-illness study; methods and guideline-rates for economic evaluations in health care. Diemen, The Netherlands: College voor Zorgverzekeringen, 2004.
12. The Dutch Bureau of Statistics (Centroal Bureau voor de Statistiek). Voorburg/Heerlen, The Netherlands: The Dutch Bureau of Statistics, 1999.
13. Hoeymans N, van Lindert H, Westert GP. The health status of the Dutch population as assessed by the EQ-6D. Qual Life Res 2005;14:655-63.
14. Chorus AM, Miedema HS, Boonen A, van der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003;62:1178-84.
15. Bakham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology (Oxford), 2005;44:1277-81.
16. Heiberg MS, Nordvog BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12.
17. Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
18. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
19. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
20. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
21. Boonen A, van den Heuvel R, van Tubergen A, Goossens M, Severens JL, van der Heijde D, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005;64:396-402.
22. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401.